{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:59:45Z","timestamp":1781643585839,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hyperprolactinemia is mainly due to pituitary disorders including prolactinomas but other causes including adverse drug reactions exist. This study aimed to assess the frequency and pattern of serum prolactin measurements in a population-wide cohort in Central Region Denmark (1.32 mill inhabitants) from 2011 to 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the Central Denmark Region\u2019s data warehouse, we identified all individuals who had at least one prolactin measurement in the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 84,145 individuals who had at least one measurement of prolactin. Among these, 17,008 (20.3%) had at least one measurement of elevated prolactin corresponding to an incidence of 107 per 100.000 person-years. Hyperprolactinemia, defined by at least two elevated prolactin concentrations, occurred in 5,810 individuals (73.9% female), with an incidence of 36.7 per 100.000 person-years. Only 12.7% of individuals with hyperprolactinemia were treated with dopamine agonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We found a substantial number of repeated prolactin measurements, many of which did not seem to lead to clinical action. The findings support the need for guidelines for management of hyperprolactinemia to ensure proper utilization of health resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01647-z","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:18:44Z","timestamp":1774426724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prolactin measurements in a real-life setting: a population-based cohort study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9590-7398","authenticated-orcid":false,"given":"Christoffer","family":"Krogager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Otto Lunde","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus H\u00f8jbjerg","family":"Gravholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstine","family":"Stochholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"4","key":"1647_CR1","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME et al (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80(4):1523\u20131631","journal-title":"Physiol Rev"},{"issue":"11","key":"1647_CR2","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1172\/JCI20401","volume":"112","author":"S Melmed","year":"2003","unstructured":"Melmed S (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112(11):1603\u20131618","journal-title":"J Clin Invest"},{"issue":"11","key":"1647_CR3","doi-asserted-by":"publisher","first-page":"e12888","DOI":"10.1111\/jne.12888","volume":"32","author":"F Lopez-Vicchi","year":"2020","unstructured":"Lopez-Vicchi F et al (2020) Metabolic functions of prolactin: Physiological and pathological aspects. J Neuroendocrinol 32(11):e12888","journal-title":"J Neuroendocrinol"},{"issue":"12","key":"1647_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 19(12):722\u2013740","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"1647_CR5","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1210\/jc.2009-0177","volume":"94","author":"M Kars","year":"2009","unstructured":"Kars M et al (2009) Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94(8):2729\u20132734","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1647_CR6","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1210\/jc.2011-3257","volume":"97","author":"C Steffensen","year":"2012","unstructured":"Steffensen C et al (2012) Heart valve disease among patients with hyperprolactinemia: a nationwide population-based cohort study. J Clin Endocrinol Metab 97(5):1629\u20131634","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1647_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1515\/cclm-2012-0769","volume":"51","author":"G F\u00e9rard","year":"2013","unstructured":"F\u00e9rard G, Dybkaer R (2013) Recommendations for clinical laboratory science reports regarding properties, units, and symbols: the NPU format. Clin Chem Lab Med 51(5):959\u2013966","journal-title":"Clin Chem Lab Med"},{"key":"1647_CR8","unstructured":"The selection and use of essential medicines (2006) Report of the WHO expert committee, (2005) (including the 14th model list of essential medicines). World Health Organ Tech Rep Ser (933):1-119. back cover"},{"key":"1647_CR9","unstructured":"https:\/\/www.fagperson.auh.dk\/afdelinger\/blodprover-og-biokemi\/analysefortegnelsen\/hospital\/#1118067"},{"issue":"3","key":"1647_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377\u2013382","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1647_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12905-023-02290-7","volume":"23","author":"E Odongo","year":"2023","unstructured":"Odongo E et al (2023) Prevalence and effects of menstrual disorders on quality of life of female undergraduate students in Makerere University College of health sciences, a cross sectional survey. BMC Womens Health 23(1):152","journal-title":"BMC Womens Health"},{"issue":"2","key":"1647_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/cen.14402","volume":"95","author":"M Phylactou","year":"2021","unstructured":"Phylactou M et al (2021) Clinical and biochemical discriminants between functional hypothalamic amenorrhoea (FHA) and polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 95(2):239\u2013252","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1647_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1750-1172-1-9","volume":"1","author":"P Beck-Peccoz","year":"2006","unstructured":"Beck-Peccoz P, Persani L (2006) Premature ovarian failure. Orphanet J Rare Dis 1:9","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1647_CR14","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1093\/ejendo\/lvad096","volume":"189","author":"HJ Teede","year":"2023","unstructured":"Teede HJ et al (2023) Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol 189(2):G43\u2013g64","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1647_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/1039856220934326","volume":"29","author":"AS Jones","year":"2021","unstructured":"Jones AS et al (2021) Prolactin ordering patterns in psychiatric inpatients and the impact this has on patient management. Australas Psychiatry 29(3):282\u2013285","journal-title":"Australas Psychiatry"},{"issue":"2 Suppl","key":"1647_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/0269881107086516","volume":"22","author":"J Walters","year":"2008","unstructured":"Walters J, Jones I (2008) Clinical questions and uncertainty\u2013prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol 22(2 Suppl):82\u201389","journal-title":"J Psychopharmacol"},{"issue":"4","key":"1647_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1046\/j.1365-2265.1998.00569.x","volume":"49","author":"A Pollock","year":"1998","unstructured":"Pollock A, McLaren EH (1998) Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol (Oxf) 49(4):513\u2013516","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1647_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4158\/EP.6.6.425","volume":"6","author":"AE Kearns","year":"2000","unstructured":"Kearns AE et al (2000) Risperidone-associated hyperprolactinemia. Endocr Pract 6(6):425\u2013429","journal-title":"Endocr Pract"},{"issue":"4","key":"1647_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/02813432.2021.1970945","volume":"39","author":"MK Andersen","year":"2021","unstructured":"Andersen MK et al (2021) Defensive medicine in Danish general practice. Types of defensive actions and reasons for practicing defensively. Scand J Prim Health Care 39(4):413\u2013418","journal-title":"Scand J Prim Health Care"},{"issue":"2","key":"1647_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4103\/2141-9248.113688","volume":"3","author":"MS Sekhar","year":"2013","unstructured":"Sekhar MS, Vyas N (2013) Defensive medicine: a bane to healthcare. Ann Med Health Sci Res 3(2):295\u2013296","journal-title":"Ann Med Health Sci Res"},{"key":"1647_CR21","unstructured":"https:\/\/www.dsam.dk\/vejledninger\/bloedningsforstyrrelser\/bilag#1-hormonanalyser-i-relation-til-bloedningsforstyrrelser. [cited 2024 3008]."},{"issue":"1","key":"1647_CR22","first-page":"1","volume":"26","author":"HO Birk","year":"2024","unstructured":"Birk HO et al (2024) Denmark: health system review. Health Syst Transit 26(1):1\u2013186","journal-title":"Health Syst Transit"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01647-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:50:05Z","timestamp":1781643005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01647-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01647-z","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}